Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
Related Keywords
Netherlands , Amsterdam , Noord Holland , Canada , Toronto , Ontario , Sharon Cohen , Tim Mooney , Toronto Memory Program , Alzheimer Association International Conference , Regeneron Pharmaceuticals Inc , Association International Conference , Regeneron Pharmaceuticals , Bio Developments , Emerging Markets , Alzheimer 039s Disease , Lzheimer , Clinical Trial ,
comparemela.com © 2020. All Rights Reserved.